Neurology

Back to articles

Alemtuzumab for multiple sclerosis: Effective, but at what cost?

KEY POINT

 

Alemtuzumab (Campath—Genzyme) lowered relapse rates more effectively than interferon beta-1a (Rebif—EMD Serono) in individuals with relapsing–remitting multiple sclerosis, according to two recent trials. Alemtuzumab also reduced disability compared with interferon beta-1a in one trial.